Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GemPOx and HDC/AuHSCR for Recurrent Intracranial Germ Cell Tumors
NCT01270724Phase 2Completed
- Sponsor
- Nationwide Children's Hospital
- Start
- Aug 2010
- Primary completion
- Oct 2019
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine, paclitaxel and oxaliplatin in intracranial germ cell tumor (ICGCT), sponsored by Nationwide Children's Hospital. Primary endpoints: Response Rate and Rate of Completion of Induction Chemotherapy and Progression to HDC with AuHPCR at 44 months. Started Aug 2010; status: completed.
02
Drugs
gemcitabinepaclitaxeloxaliplatin
03
Conditions
intracranial germ cell tumor (ICGCT)
Beyond the preview
Go deeper on NCT01270724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01270724.